Agency stated that documentation sent by Precise Medicines will be analyzed; Covaxin is developed by the Indian laboratory Bharat Biotech
A National Health Surveillance Agency (Anvisa) he said on Tuesday, 29, that he received the request for emergency use on an experimental basis of the Indian vaccine Covaxin, manufactured by the Indian laboratory Bharat Biotech and represented in the Brazil by the company Needs Marketing of Medicines. According to the agency, the screening of documents sent by Need will be done in the next 24 hours and, if any paper is missing, the laboratory should be activated with a request for additional information. As there is no clinical development of the vaccine in Brazil, Anvisa must respond about the emergency use within 30 days from the moment all the required documents are in the agency’s hand.
The negotiation of Covaxin by Brazil became the focus of the CPI of Covid-19 after a statement by public servant Luís Ricardo Miranda and federal deputy Luís Miranda (DEM) citing alleged irregularities in the purchase of the immunizing agent. According to the parliamentarian’s version, when citing signs of corruption in the purchase of Covaxin in conversation with Jair Bolsonaro, the president would have committed himself to transmitting the information to the director general of the Federal Police. In addition, according to the DEM deputy, Bolsonaro would have cited the leader of his government in the Chamber of Deputies, Ricardo Barros (PP-PR), as “the owner of the roll”, which also involves the company, Need Medicines, which brokered the acquisition of immunizing agent manufactured by the Bharat Biotech laboratory. Because of this speech, senators filed a criminal report in the Federal Supreme Court (STF) asking for an investigation of Bolsonaro for an alleged crime of malfeasance.